Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 2/20 | 0.49 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 8/20 | 0.37 |
| ▸ | RAB9A | P51151 | 8/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.31 |
| ▸ | IL2 | P60568 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL720496 | 0.73 | STIM1 (0.64) | STIM1ORAI1NPC1RAB9AMEN1 | |
| SCHEMBL767072 | 0.73 | STIM1 (0.55) | STIM1ORAI1NPC1RAB9AMEN1 | |
| SCHEMBL12155806 | 0.67 | STIM1 (0.68) | STIM1ORAI1NPC1RAB9AMEN1 | |
| SCHEMBL12155812 | 0.66 | STIM1 (0.67) | STIM1ORAI1NPC1RAB9AMEN1 | |
| SCHEMBL10201085 | 0.66 | STIM1 (1.00) | STIM1ORAI1NPC1RAB9AMEN1 | |
| SCHEMBL767089 | 0.66 | KMT2A (0.40) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL12155838 | 0.64 | NPC1 (0.56) | STIM1ORAI1NPC1RAB9AMEN1 | |
| SCHEMBL720890 | 0.64 | STIM1 (0.62) | STIM1ORAI1NPC1RAB9AMAPT | |
| SCHEMBL12155821 | 0.64 | STIM1 (0.53) | STIM1ORAI1NPC1RAB9AMEN1 | |
| SCHEMBL17805364 | 0.61 | STIM1 (0.48) | STIM1ORAI1NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619200-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012040511-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071516-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071516-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885NPC1 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.